Conflict of interest
Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin – Consensus of the lymphoma group of the Working Group Dermatologic Oncology
Article first published online: 2 JAN 2013
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Volume 11, Issue 4, pages 338–347, April 2013
How to Cite
Assaf, C., Becker, J. C., Beyer, M., Cozzio, A., Dippel, E., Klemke, C.-D., Kurschat, P., Weichenthal, M. and Stadler, R. (2013), Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin – Consensus of the lymphoma group of the Working Group Dermatologic Oncology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 11: 338–347. doi: 10.1111/ddg.12012
The discussion on the use of liposmoal doxorubicin took place within the context of an Advisory Board meeting supported by the TEVA company.
- Issue published online: 10 APR 2013
- Article first published online: 2 JAN 2013
- Manuscript Accepted: 6 NOV 2012
- Manuscript Received: 3 SEP 2012
Systemic treatment with pegylated liposomal doxorubicin is an established second-line treatment of advanced cutaneous T-cell lymphoma. Pegylated liposomal doxorubicin (PLD) is currently unavailable, therefore, clinical studies investigating the efficacy of non-pegylated liposomal formula (NPLD) have been analyzed.
Since clinical trials comparing PLD and NPLD in CTCL do not exist, the clinical use of NPLD including safety and efficiency profile in other types of non-Hodgkin lymphoma were analyzed.
Clinical trials show a comparable efficacy of NPLD and PLD in non-Hodgkin lymphoma. The dosage of NPLD used in the treatment of systemic lymphoma within polychemotherapy regimens was 50 mg/m2 every three weeks. Overall response was 75–95%, including a complete remission rate of 65–80% and 2- and 3-year overall survival rates of 55–75%. These data indicate that the non-pegylated formula of doxorubicin has a similar antitumor effect as the pegylated one but shows reduced cardiotoxicity. The palmoplantar erythrodysesthesia frequently observed in PLD has not been observed with the use of the NPLD.
The clinical use of NPLD in the treatment of CTCL is reasonable. In analogy to the clinical trials of NPLD in non-Hodgkin lymphoma a dosage of 50 mg/m2 every three weeks is recommended for the treatment of CTCL.